Confluence of obesity and MAFLD during Covid‐19 pandemic in a developing country

Yovera, Jhean Gabriel Gonzáles; Concepción-Zavaleta, Marcio José; Arroyo, Julia; Marreros, Diego Martín Moreno

doi:10.1002/edm2.189

Cited by 2 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given that metabolic elements like obesity and diabetes are well-recognized to be associated with severe cases of COVID-19 and predispose to high risk of mortality (31) , it is reasonable to infer that a poorer prognosis for COVID-19 is also linked to MAFLD (32) . The reasons behind these unfavorable outcomes have sparked debate, with various potential mechanisms coming into play.…”

Section: Discussionmentioning

confidence: 99%

Study on the Impact of metabolic associated fatty liver disease (MAFLD) on patients with Corona Virus Disease – 2019 (COVID-19)

Oraby,

Mazoun,

Mohamed

et al. 2023

Benha Medical Journal

View full text Add to dashboard Cite

Purpose: This study's purpose was to assess the impact of metabolic associated fatty liver disease (MAFLD) on the outcome of patients affected by Corona Virus Disease -2019 (COVID-19). Patients and Methods: This prospective observational study `was conducted on patients affected by COVID-19 who were treated at our Hospital from January 2022 to February 2023. The study involved 200 adult patients with confirmed COVID-19, excluding those with other chronic hepatic disorders, and included comprehensive clinical, laboratory, and ultrasonographic assessments. The existence of MAFLD was assessed as newly established, and the COVID-19 severity was evaluated per the Egyptian protocol, and the diagnosis of MAFLD followed international consensus criteria. Results: Patients with MAFLD and COVID-19 (Group I) had a significantly higher number of patients with severe disease (n = 60, 60%) than patients with COVID-19 alone (Group II) (n = 21, 21%, p < 0.001). The mortality rate was 11% (n = 22), with a significantly higher rate encountered in Group I (n = 16, 16% vs. n = 6, 6%, p = 0.024). Conclusion:Patients with MAFLD exhibited distinct clinical and laboratory features and were more likely to develop severe COVID-19, with a higher mortality rate.

show abstract

Section: Discussionmentioning

confidence: 99%

Study on the Impact of metabolic associated fatty liver disease (MAFLD) on patients with Corona Virus Disease – 2019 (COVID-19)

Oraby,

Mazoun,

Mohamed

et al. 2023

Benha Medical Journal

View full text Add to dashboard Cite

show abstract

COVID-19 and MAFLD/NAFLD: An updated review

2023

View full text Add to dashboard Cite

The COVID-19 pandemic is ongoing and places a substantial burden on healthcare systems worldwide. As we further shed light on different disease characteristics, we identify more and more groups of people at higher risk of poor COVID-19 outcomes. Metabolic-associated fatty liver disease (MAFLD) (previously non-alcoholic fatty liver disease or NAFLD) is a common metabolic disorder characterized by fat accumulation and liver fibrosis. Given its close correlation with metabolic syndrome, an established risk factor for severe COVID-19, it is necessary to investigate its interplay with the novel coronavirus. In this study, we review the available data on COVID-19 prognosis, treatment and prevention options in patients with MAFLD, and the effect that the disease and the pandemic have on MAFLD care. Furthermore, we point out the gaps in the current literature to accentuate the work that needs to be done to improve MAFLD care during the pandemic and beyond.

show abstract

Confluence of obesity and MAFLD during Covid‐19 pandemic in a developing country

Abstract: The direct relation between the overweight/obesity, MAFLD and the severity SARS‐CoV‐2 infection. increase number of cases of obesity and MAFLD is an important risk factor for high mortality of COVID‐19 patients

Cited by 2 publications

References 6 publications

Study on the Impact of metabolic associated fatty liver disease (MAFLD) on patients with Corona Virus Disease – 2019 (COVID-19)

Study on the Impact of metabolic associated fatty liver disease (MAFLD) on patients with Corona Virus Disease – 2019 (COVID-19)

COVID-19 and MAFLD/NAFLD: An updated review

Contact Info

Product

Resources

About